We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App





COVID-19, Flu and RSV Combination Test to Increase Testing Capacity and Speed Time to Diagnosis

By LabMedica International staff writers
Posted on 01 Jul 2022
Print article
Image: BD MAX molecular diagnostic respiratory viral panel is CE marked to IVD directive (Photo courtesy of BD)
Image: BD MAX molecular diagnostic respiratory viral panel is CE marked to IVD directive (Photo courtesy of BD)

A new molecular diagnostic combination test for SARS-CoV-2, Influenza A + B and Respiratory Syncytial Virus (RSV) can help eliminate the need for multiple tests or doctor visits and aid clinicians in implementing the right treatment plan quickly. The co-testing approach can also help to increase testing capacity during the busy flu season and speed the time to diagnosis.

Becton, Dickinson and Company (BD, Franklin Lakes, NJ, USA) has launched the BD MAX Respiratory Viral Panel (RVP) which uses a single nasal swab or a single nasopharyngeal swab sample to determine if a patient has COVID-19 or the flu or RSV. The BD MAX RVP assay is an RT- PCR assay that detects and differentiates the mRNA of SARS-CoV-2, flu A, flu B and RSV in approximately two hours, with the easy-to-use and automated workflow of the BD MAX System. The BD MAX System, a molecular diagnostic platform, is already in use at thousands of laboratories worldwide, and each unit is capable of analyzing hundreds of samples over a 24-hour period.

The BD RVP assay for BD MAX System is an important addition to the extensive number of assays available on the system across respiratory, STI, gastrointestinal, women's health and health care associated infections. The broad menu of assays in combination with the open system capabilities on a fully automated sample-to-result molecular platform make the BD MAX System a valued platform for infectious disease testing in thousands of labs worldwide. BD MAX RVP is currently available in countries that recognize the CE mark. BD plans to submit for Emergency Use Authorization from the U.S. Food and Drug Administration in the coming weeks.

"SARS-Cov-2, influenza and RSV are a triple threat, as patient symptoms and clinical presentation can be nearly identical," said Nikos Pavlidis, vice president of Molecular Diagnostics at BD. "A combined testing panel is key to enabling clinicians to quickly and efficiently diagnose, differentiate and treat patients to help manage the spread of the infections."

Related Links:
BD 

Gold Supplier
SARS-CoV-2 Control
VIROTROL SARS-CoV-2 (IVD/CE Mark)
New
Zika Virus ELISA Test
RecombiLISA Zika IgM ELISA CE
New
Multiplex Molecular Panel
ARIES Flu A/B & RSV+SARS‑CoV‑2 Assay (CE-IVD)
New
Multichannel Adjustable-Volume Pipettor
Cole-Parmer Essentials

Print article

Channels

Molecular Diagnostics

view channel
Image: A new blood test could noninvasively and inexpensively detect colorectal cancer (Photo courtesy of Pexels)

Novel Blood Test Could Detect Early-Onset Colorectal Cancer

Colorectal cancer is the fourth most common cancer, according to the U.S. Centers for Disease Control and Prevention. The rate of colon or rectal cancers in people younger than 50 years old has been on... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.